Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Head and Neck Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 169 articles:
HTML format
Text format



Single Articles


    February 2020
  1. FIETKAU R, Hecht M, Hofner B, Lubgan D, et al
    Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
    Radiother Oncol. 2020;144:209-217.
    PubMed     Text format     Abstract available


  2. SARAH D, Daan N, Frederic D, Jean-Francois D, et al
    Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome.
    Radiother Oncol. 2020 Feb 7. pii: S0167-8140(20)30017.
    PubMed     Text format     Abstract available


    January 2020
  3. LI WZ, Liu GY, Lin LF, Lv SH, et al
    MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it.
    Radiother Oncol. 2020;145:101-108.
    PubMed     Text format     Abstract available


    November 2019
  4. BHATTACHARYYA T, Koto M, Ikawa H, Hayashi K, et al
    Assessment of risk factors associated with development of oronasal fistula as a late complication after carbon-ion radiotherapy for head and neck cancer.
    Radiother Oncol. 2019;144:53-58.
    PubMed     Text format     Abstract available


    October 2019
  5. LEE JY, Kim YA, Kim HS, Back JH, et al
    Radiotherapy can increase the risk of ischemic cerebrovascular disease in head and neck cancer patients: A Korean population-based cohort study.
    Radiother Oncol. 2019 Oct 17. pii: S0167-8140(19)33114.
    PubMed     Text format     Abstract available


    September 2019
  6. YANG Z, Zhang X, Wang X, Zhu XR, et al
    Multiple-CT optimization: An adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
    Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33094.
    PubMed     Text format     Abstract available


  7. ELBERS JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, et al
    Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33046.
    PubMed     Text format     Abstract available


  8. WANG J, Qing G, Ou X, Hu W, et al
    The impact of target dosimetry on patients' locoregional recurrence in nasopharyngeal carcinoma: A propensity score-matched analysis.
    Radiother Oncol. 2019 Sep 20. pii: S0167-8140(19)33074.
    PubMed     Text format     Abstract available


    August 2019
  9. CHAN RJ, Blades R, Jones L, Downer TR, et al
    A single-blind, randomised controlled trial of StrataXRT(R) - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer.
    Radiother Oncol. 2019 Aug 21. pii: S0167-8140(19)33004.
    PubMed     Text format     Abstract available


  10. KUBO N, Kubota Y, Kawamura H, Oike T, et al
    Dosimetric parameters predictive of nasolacrimal duct obstruction after carbon-ion radiotherapy for head and neck carcinoma.
    Radiother Oncol. 2019 Aug 19. pii: S0167-8140(19)33015.
    PubMed     Text format     Abstract available


  11. VAN DEN BOSCH S, Doornaert PAH, Dijkema T, Zwijnenburg EM, et al
    (18)F-FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival.
    Radiother Oncol. 2019 Aug 19. pii: S0167-8140(19)33018.
    PubMed     Text format     Abstract available


  12. HEUKELOM J, Kantor ME, Mohamed ASR, Elhalawani H, et al
    Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33027.
    PubMed     Text format     Abstract available


  13. ZHAN M, Zheng H, Yang Y, Xu T, et al
    Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33024.
    PubMed     Text format     Abstract available


  14. RADES D, Narvaez CA, Splettstosser L, Domer C, et al
    A randomized trial (RAREST-01) comparing Mepitel(R) Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33016.
    PubMed     Text format     Abstract available


    July 2019
  15. YU S, Zhang W, Ni W, Xiao Z, et al
    A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy.
    Radiother Oncol. 2019;140:159-166.
    PubMed     Text format     Abstract available


    June 2019
  16. CHOW JCH, Cheung KM, Au KH, Zee BCY, et al
    Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose-toxicity relationship.
    Radiother Oncol. 2019;138:93-98.
    PubMed     Text format     Abstract available


  17. HUANG L, Zhang Y, Liu Y, Li H, et al
    Prognostic value of retropharyngeal lymph node metastasis laterality in nasopharyngeal carcinoma and a proposed modification to the UICC/AJCC N staging system.
    Radiother Oncol. 2019;140:90-97.
    PubMed     Text format     Abstract available


  18. MOAN JM, Amdal CD, Malinen E, Svestad JG, et al
    The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
    Radiother Oncol. 2019;140:54-61.
    PubMed     Text format     Abstract available


  19. BATES JE, Morris CG, Hitchcock KE, Dziegielewski PT, et al
    Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status.
    Radiother Oncol. 2019;140:6-9.
    PubMed     Text format     Abstract available


    May 2019
  20. VAN DER VEEN J, Willems S, Deschuymer S, Robben D, et al
    Benefits of deep learning for delineation of organs at risk in head and neck cancer.
    Radiother Oncol. 2019;138:68-74.
    PubMed     Text format     Abstract available


  21. WILKIE JR, Mierzwa ML, Yao J, Eisbruch A, et al
    Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy.
    Radiother Oncol. 2019;137:167-174.
    PubMed     Text format     Abstract available


  22. KOIVUNORO H, Kankaanranta L, Seppala T, Haapaniemi A, et al
    Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival.
    Radiother Oncol. 2019;137:153-158.
    PubMed     Text format     Abstract available


  23. YAO JJ, Qi ZY, Liu ZG, Jiang GM, et al
    Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Radiother Oncol. 2019;137:137-144.
    PubMed     Text format     Abstract available


  24. GANJU RG, Morse R, Hoover A, TenNapel M, et al
    The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation.
    Radiother Oncol. 2019;137:117-124.
    PubMed     Text format     Abstract available


  25. LIU SL, Sun XS, Yan JJ, Chen QY, et al
    Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Radiother Oncol. 2019;137:83-94.
    PubMed     Text format     Abstract available


  26. BRENNER B, Purim O, Gordon N, Goshen-Lago T, et al
    The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial.
    Radiother Oncol. 2019;134:74-80.
    PubMed     Text format     Abstract available


  27. LI HJ, Hu YY, Huang L, Zhou J, et al
    Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: A double-center retrospective investigation.
    Radiother Oncol. 2019;134:37-43.
    PubMed     Text format     Abstract available


    April 2019
  28. VAN DER VEEN J, Gulyban A, Nuyts S
    Interobserver variability in delineation of target volumes in head and neck cancer.
    Radiother Oncol. 2019;137:9-15.
    PubMed     Text format     Abstract available


  29. MENECEUR S, Lock S, Gudziol V, Hering S, et al
    Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
    Radiother Oncol. 2019;137:24-31.
    PubMed     Text format     Abstract available


  30. ZHUO X, Huang X, Yan M, Li H, et al
    Comparison between high-dose and low-dose intravenous methylprednisolone therapy in patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2019;137:16-23.
    PubMed     Text format     Abstract available


  31. HAYASHI K, Koto M, Ikawa H, Hagiwara Y, et al
    Feasibility of Re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy.
    Radiother Oncol. 2019;136:148-153.
    PubMed     Text format     Abstract available


  32. WAGENAAR D, Kierkels RGJ, Free J, Langendijk JA, et al
    Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients.
    Radiother Oncol. 2019;136:71-77.
    PubMed     Text format     Abstract available


  33. DENG W, Xu C, Liu A, van Rossum PSN, et al
    The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.
    Radiother Oncol. 2019;133:9-15.
    PubMed     Text format     Abstract available


  34. CHO WK, Oh D, Kim HK, Ahn YC, et al
    Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.
    Radiother Oncol. 2019;133:87-92.
    PubMed     Text format     Abstract available


  35. LIAO W, Zheng Y, Bi S, Zhang B, et al
    Carotid stenosis prevalence after radiotherapy in nasopharyngeal carcinoma: A meta-analysis.
    Radiother Oncol. 2019;133:167-175.
    PubMed     Text format     Abstract available



  36. Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating.
    Radiother Oncol. 2019;133:35-42.
    PubMed     Text format     Abstract available


  37. APOLLE R, Bruckner S, Frosch S, Rehm M, et al
    Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma.
    Radiother Oncol. 2019;133:28-34.
    PubMed     Text format     Abstract available


    March 2019
  38. KOSMIN M, Ledsam J, Romera-Paredes B, Mendes R, et al
    Rapid advances in auto-segmentation of organs at risk and target volumes in head and neck cancer.
    Radiother Oncol. 2019;135:130-140.
    PubMed     Text format     Abstract available


  39. SMITH J, Nastasi D, Tso R, Vangaveti V, et al
    The effects of continued smoking in head and neck cancer patients treated with radiotherapy: A systematic review and meta-analysis.
    Radiother Oncol. 2019;135:51-57.
    PubMed     Text format     Abstract available


  40. REID P, Marcu LG, Olver I, Moghaddasi L, et al
    Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response.
    Radiother Oncol. 2019;135:1-12.
    PubMed     Text format     Abstract available


  41. CAI J, Cheng J, Li H, Lin WJ, et al
    A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2019;132:34-41.
    PubMed     Text format     Abstract available


  42. DE KRUIJF W, Timmers A, Dekker J, Boing-Messing F, et al
    Occurrence and mechanism of visual phosphenes in external photon beam radiation therapy and how to influence them.
    Radiother Oncol. 2019;132:109-113.
    PubMed     Text format     Abstract available


    February 2019
  43. WAN Y, Tian L, Zhang G, Xin H, et al
    The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Radiother Oncol. 2019;131:35-44.
    PubMed     Text format     Abstract available


  44. CUBILLOS-MESIAS M, Troost EGC, Lohaus F, Agolli L, et al
    Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation.
    Radiother Oncol. 2019;131:127-134.
    PubMed     Text format     Abstract available


  45. VAARWERK B, Hol MLF, Schoot RA, Breunis WB, et al
    AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma.
    Radiother Oncol. 2019;131:21-26.
    PubMed     Text format     Abstract available


  46. MOLLER DS, Alber M, Nordsmark M, Nyeng TB, et al
    Validation of a robust strategy for proton spot scanning for oesophageal cancer in the presence of anatomical changes.
    Radiother Oncol. 2019;131:174-178.
    PubMed     Text format     Abstract available


  47. MCDOWELL LJ, Ringash J, Xu W, Chan B, et al
    A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy.
    Radiother Oncol. 2019;131:179-185.
    PubMed     Text format     Abstract available


  48. ZHU JH, Wang J, Wang YG, Li M, et al
    Prospect of robotic assistance for fully automated brachytherapy seed placement into skull base: Experimental validation in phantom and cadaver.
    Radiother Oncol. 2019;131:160-165.
    PubMed     Text format     Abstract available


    January 2019
  49. TOL JP, Dahele M, Gregoire V, Overgaard J, et al
    Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance.
    Radiother Oncol. 2019;130:75-81.
    PubMed     Text format     Abstract available


  50. BRUIJNEN T, Stemkens B, Terhaard CHJ, Lagendijk JJW, et al
    Intrafraction motion quantification and planning target volume margin determination of head-and-neck tumors using cine magnetic resonance imaging.
    Radiother Oncol. 2019;130:82-88.
    PubMed     Text format     Abstract available


  51. DUTZ A, Lock S
    Competing risks in survival data analysis.
    Radiother Oncol. 2019;130:185-189.
    PubMed     Text format     Abstract available


  52. BANDURSKA-LUQUE A, Lock S, Haase R, Richter C, et al
    FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
    Radiother Oncol. 2019;130:97-103.
    PubMed     Text format     Abstract available


  53. GAWRYSZUK A, Bijl HP, Holwerda M, Halmos GB, et al
    Functional Swallowing Units (FSUs) as organs-at-risk for radiotherapy. PART 2: Advanced delineation guidelines for FSUs.
    Radiother Oncol. 2019;130:68-74.
    PubMed     Text format     Abstract available


  54. HAGUE C, Beasley W, Dixon L, Gaito S, et al
    Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring.
    Radiother Oncol. 2019;130:56-61.
    PubMed     Text format     Abstract available


  55. WELCH ML, McIntosh C, Haibe-Kains B, Milosevic MF, et al
    Vulnerabilities of radiomic signature development: The need for safeguards.
    Radiother Oncol. 2019;130:2-9.
    PubMed     Text format     Abstract available



  56. A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findi
    Radiother Oncol. 2019;130:46-55.
    PubMed     Text format     Abstract available


    November 2018
  57. YAO JJ, Zhang F, Gao TS, Zhang WJ, et al
    Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Radiother Oncol. 2018 Nov 14. pii: S0167-8140(18)33542.
    PubMed     Text format     Abstract available


  58. TOPKAN E, Yildirim BA
    Epoetin receptor status may alter the outcomes in head and neck cancers treated with radiotherapy and darbepoetin-alpha.
    Radiother Oncol. 2018 Nov 7. pii: S0167-8140(18)33397.
    PubMed     Text format    


    October 2018
  59. LIANG SB, Zhang N, Chen DM, Yang XL, et al
    Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2018 Oct 23. pii: S0167-8140(18)33522.
    PubMed     Text format     Abstract available


  60. YILMAZ MT, Elmali A, Yazici G
    Comments on "High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer".
    Radiother Oncol. 2018 Oct 17. pii: S0167-8140(18)33506.
    PubMed     Text format    


  61. KANAYAMA N, Kierkels RGJ, van der Schaaf A, Steenbakkers RJHM, et al
    External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6months after definitive radiotherapy for head and neck cancer.
    Radiother Oncol. 2018 Oct 6. pii: S0167-8140(18)33496.
    PubMed     Text format     Abstract available


    September 2018
  62. HUANG XD, Zhou GQ, Lv JW, Zhou HQ, et al
    Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Radiother Oncol. 2018 Sep 27. pii: S0167-8140(18)33487.
    PubMed     Text format     Abstract available


  63. OVERGAARD J, Alsner J
    Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Radiother Oncol. 2018 Sep 21. pii: S0167-8140(18)33452.
    PubMed     Text format    


  64. BIAU J, Dunet V, Lapeyre M, Simon C, et al
    Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers.
    Radiother Oncol. 2018 Sep 8. pii: S0167-8140(18)33458.
    PubMed     Text format     Abstract available


  65. KAMAL M, Mohamed ASR, Volpe S, Zaveri J, et al
    Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry.
    Radiother Oncol. 2018;128:442-451.
    PubMed     Text format     Abstract available


  66. VAN DIJK LV, Thor M, Steenbakkers RJHM, Apte A, et al
    Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia.
    Radiother Oncol. 2018;128:459-466.
    PubMed     Text format     Abstract available


  67. DIXON L, Ramasamy S, Cardale K, Dyker K, et al
    Long term patient reported swallowing function following chemoradiotherapy for oropharyngeal carcinoma.
    Radiother Oncol. 2018;128:452-458.
    PubMed     Text format     Abstract available


    August 2018
  68. OU D, Adam J, Garberis I, Blanchard P, et al
    Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.
    Radiother Oncol. 2018 Aug 29. pii: S0167-8140(18)33451.
    PubMed     Text format     Abstract available


  69. DE VEIJ MESTDAGH PD, Janssen T, Lamers E, Carbaat C, et al
    SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33422.
    PubMed     Text format     Abstract available


  70. LEGER S, Zwanenburg A, Pilz K, Zschaeck S, et al
    CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33419.
    PubMed     Text format     Abstract available


  71. LI YJ, Luo Y, Xie XQ, Li P, et al
    The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
    Radiother Oncol. 2018 Aug 3. pii: S0167-8140(18)33421.
    PubMed     Text format     Abstract available


    July 2018
  72. NOBLE DJ, Yeap PL, Seah SYK, Harrison K, et al
    Anatomical change during radiotherapy for head and neck cancer, and its effect on delivered dose to the spinal cord.
    Radiother Oncol. 2018 Jul 23. pii: S0167-8140(18)33396.
    PubMed     Text format     Abstract available


  73. VAN DEN BOSCH S, Dijkema T, Philippens MEP, Terhaard CHJ, et al
    Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of (18)F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33352.
    PubMed     Text format     Abstract available


  74. NAVRAN A, Heemsbergen W, Janssen T, Hamming-Vrieze O, et al
    The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT).
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33347.
    PubMed     Text format     Abstract available


    May 2018
  75. TAO Y, Faivre L, Laprie A, Boisselier P, et al
    Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
    Radiother Oncol. 2018 May 18. pii: S0167-8140(18)30246.
    PubMed     Text format     Abstract available


  76. WINTER RM, Leibfarth S, Schmidt H, Zwirner K, et al
    Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients.
    Radiother Oncol. 2018 May 7. pii: S0167-8140(18)30209.
    PubMed     Text format     Abstract available


  77. MICHIELS S, Poels K, Crijns W, Delombaerde L, et al
    Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac.
    Radiother Oncol. 2018 May 5. pii: S0167-8140(18)30212.
    PubMed     Text format     Abstract available


  78. VAN DEN BOSCH S, Vogel WV, Raaijmakers CP, Dijkema T, et al
    Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation.
    Radiother Oncol. 2018 May 3. pii: S0167-8140(18)30211.
    PubMed     Text format     Abstract available


  79. CHAO M, Wei J, Narayanasamy G, Yuan Y, et al
    Three-dimensional cluster formation and structure in heterogeneous dose distribution of intensity modulated radiation therapy.
    Radiother Oncol. 2018;127:197-205.
    PubMed     Text format     Abstract available


  80. DELANEY AR, Dahele M, Slotman BJ, Verbakel WFAR, et al
    Is accurate contouring of salivary and swallowing structures necessary to spare them in head and neck VMAT plans?
    Radiother Oncol. 2018;127:190-196.
    PubMed     Text format     Abstract available


  81. MOORE SJ, Herst PM, Louwe RJW
    Review of the patient positioning reproducibility in head-and-neck radiotherapy using Statistical Process Control.
    Radiother Oncol. 2018;127:183-189.
    PubMed     Text format     Abstract available


    April 2018
  82. MURTHY V, Lewis S, Kannan S, Khadanga CR, et al
    Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study.
    Radiother Oncol. 2018 Apr 30. pii: S0167-8140(18)30113.
    PubMed     Text format     Abstract available


  83. GREGOIRE V, Grau C
    In reply to "A Long-Awaited Guideline for the Delineation of Primary Tumor in Head and Neck Cancer, and a Few Concerns about It" by Sezin Yuce Sari et al.
    Radiother Oncol. 2018 Apr 27. pii: S0167-8140(18)30175.
    PubMed     Text format    


  84. YUCE SARI S, Yeginer M, Cengiz M
    A long-awaited guideline for the delineation of primary tumor in head and neck cancer, and a few concerns about it.
    Radiother Oncol. 2018 Apr 24. pii: S0167-8140(18)30177.
    PubMed     Text format    


  85. ROONEY KP, Miah AB, Bhide SA, Guerrero-Urbano MT, et al
    Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.
    Radiother Oncol. 2018;127:43-48.
    PubMed     Text format     Abstract available


  86. LINGE A, Schotz U, Lock S, Lohaus F, et al
    Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
    Radiother Oncol. 2018;127:27-35.
    PubMed     Text format     Abstract available


  87. CRISPIN-ORTUZAR M, Apte A, Grkovski M, Oh JH, et al
    Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [(18)F]-Fluorodeoxyglucose positron emission tomography radiomics features.
    Radiother Oncol. 2018;127:36-42.
    PubMed     Text format     Abstract available


    March 2018
  88. TAN TH, Soon YY, Cheo T, Ho F, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Radiother Oncol. 2018 Mar 16. pii: S0167-8140(18)30123.
    PubMed     Text format     Abstract available


  89. SHURYAK I, Hall EJ, Brenner DJ
    Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications.
    Radiother Oncol. 2018 Mar 10. pii: S0167-8140(18)30098.
    PubMed     Text format     Abstract available


  90. FANG P, Jiang W, Davuluri R, Xu C, et al
    High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Radiother Oncol. 2018 Mar 9. pii: S0167-8140(18)30117.
    PubMed     Text format     Abstract available


  91. OVERGAARD J, Hoff CM, Hansen HS, Specht L, et al
    DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Radiother Oncol. 2018 Mar 6. pii: S0167-8140(18)30105.
    PubMed     Text format     Abstract available


  92. HE J, Cai L, Chen Y, He Y, et al
    Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    Radiother Oncol. 2018 Mar 5. pii: S0167-8140(18)30063.
    PubMed     Text format     Abstract available


  93. AMPFERL R, Rodemann HP, Mayer C, Hofling TTA, et al
    Glucose starvation impairs DNA repair in tumour cells selectively by blocking histone acetylation.
    Radiother Oncol. 2018;126:465-470.
    PubMed     Text format     Abstract available


    January 2018
  94. IQBAL MS, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A survey of UK national practice.
    Radiother Oncol. 2018 Jan 20. pii: S0167-8140(17)32734.
    PubMed     Text format    


  95. SHAHID IQBAL M, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review.
    Radiother Oncol. 2018 Jan 19. pii: S0167-8140(17)32766.
    PubMed     Text format     Abstract available


  96. ADENIS A, Castan F, Conroy T
    Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32773.
    PubMed     Text format    


  97. CHEN Y, Wang J
    Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32774.
    PubMed     Text format    


  98. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al.
    Radiother Oncol. 2018 Jan 4. pii: S0167-8140(17)32770.
    PubMed     Text format    


  99. ZUKAUSKAITE R, Hansen CR, Grau C, Samsoe E, et al
    Local recurrences after curative IMRT for HNSCC: Effect of different GTV to high-dose CTV margins.
    Radiother Oncol. 2018;126:48-55.
    PubMed     Text format     Abstract available


  100. GREGOIRE V, Evans M, Le QT, Bourhis J, et al
    Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Onc
    Radiother Oncol. 2018;126:3-24.
    PubMed     Text format     Abstract available


  101. HANSEN CR, Johansen J, Samsoe E, Andersen E, et al
    Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy.
    Radiother Oncol. 2018;126:43-47.
    PubMed     Text format     Abstract available


  102. LASSEN P, Lacas B, Pignon JP, Trotti A, et al
    Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
    Radiother Oncol. 2018;126:107-115.
    PubMed     Text format     Abstract available


  103. VAN DIJK LV, Noordzij W, Brouwer CL, Boellaard R, et al
    (18)F-FDG PET image biomarkers improve prediction of late radiation-induced xerostomia.
    Radiother Oncol. 2018;126:89-95.
    PubMed     Text format     Abstract available


    December 2017
  104. ZHANG Y, Li WF, Liu X, Chen L, et al
    Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Radiother Oncol. 2017 Dec 16. pii: S0167-8140(17)32756.
    PubMed     Text format     Abstract available


  105. SHIRAISHI Y, Fang P, Xu C, Song J, et al
    Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Radiother Oncol. 2017 Dec 13. pii: S0167-8140(17)32751.
    PubMed     Text format     Abstract available


  106. KAMAL M, Rosenthal DI, Volpe S, Goepfert RP, et al
    Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.
    Radiother Oncol. 2017 Dec 8. pii: S0167-8140(17)32691.
    PubMed     Text format     Abstract available


    November 2017
  107. LEE AW, Ng WT, Pan JJ, Poh SS, et al
    International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
    Radiother Oncol. 2017 Nov 15. pii: S0167-8140(17)32686.
    PubMed     Text format     Abstract available


  108. BOGOWICZ M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, et al
    Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.
    Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663.
    PubMed     Text format     Abstract available


  109. TAKAHASHI N, Umezawa R, Takanami K, Yamamoto T, et al
    Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Nov 3. pii: S0167-8140(17)32659.
    PubMed     Text format     Abstract available


    October 2017
  110. CEREDA E, Cappello S, Colombo S, Klersy C, et al
    Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy.
    Radiother Oncol. 2017 Oct 27. pii: S0167-8140(17)32655.
    PubMed     Text format     Abstract available


  111. OU D, Garberis I, Adam J, Blanchard P, et al
    Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Radiother Oncol. 2017 Oct 24. pii: S0167-8140(17)32647.
    PubMed     Text format     Abstract available


  112. DE-COLLE C, Menegakis A, Monnich D, Welz S, et al
    SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
    Radiother Oncol. 2017 Oct 20. pii: S0167-8140(17)32648.
    PubMed     Text format     Abstract available


  113. RAO AD, Coquia S, De Jong R, Gourin C, et al
    Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.
    Radiother Oncol. 2017 Oct 3. pii: S0167-8140(17)32584.
    PubMed     Text format     Abstract available


  114. COX S, Hurt C, Grenader T, Mukherjee S, et al
    The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017;125:154-159.
    PubMed     Text format     Abstract available


  115. LARUE RTHM, Van De Voorde L, van Timmeren JE, Leijenaar RTH, et al
    4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers.
    Radiother Oncol. 2017;125:147-153.
    PubMed     Text format     Abstract available


    September 2017
  116. MICHIELS S, Barragan AM, Souris K, Poels K, et al
    Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Radiother Oncol. 2017 Sep 23. pii: S0167-8140(17)32568.
    PubMed     Text format     Abstract available


  117. WOPKEN K, Bijl HP, Langendijk JA
    Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
    Radiother Oncol. 2017 Sep 21. pii: S0167-8140(17)32545.
    PubMed     Text format     Abstract available


  118. CHANG CL, Tsai HC, Lin WC, Chang JH, et al
    Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Sep 15. pii: S0167-8140(17)32548.
    PubMed     Text format     Abstract available


  119. SHIRAISHI Y, Xu C, Yang J, Komaki R, et al
    Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Radiother Oncol. 2017 Sep 13. pii: S0167-8140(17)32550.
    PubMed     Text format     Abstract available


  120. KOI L, Lock S, Linge A, Thurow C, et al
    EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
    Radiother Oncol. 2017;124:496-503.
    PubMed     Text format     Abstract available


  121. SCHNEIDER K, Bol V, Gregoire V
    Lack of differences in radiation-induced immunogenicity parameters between HPV-positive and HPV-negative human HNSCC cell lines.
    Radiother Oncol. 2017;124:411-417.
    PubMed     Text format     Abstract available


    August 2017
  122. YANG H, Chen X, Lin S, Rong J, et al
    Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Radiother Oncol. 2017 Aug 29. pii: S0167-8140(17)32479.
    PubMed     Text format     Abstract available


  123. LOCK S, Perrin R, Seidlitz A, Bandurska-Luque A, et al
    Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Radiother Oncol. 2017 Aug 23. pii: S0167-8140(17)32517.
    PubMed     Text format     Abstract available


  124. FERRIS MJ, Zhong J, Switchenko JM, Higgins KA, et al
    Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
    Radiother Oncol. 2017 Aug 18. pii: S0167-8140(17)32515.
    PubMed     Text format     Abstract available


  125. TONLAAR N, Galoforo S, Thibodeau BJ, Ahmed S, et al
    Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32501.
    PubMed     Text format     Abstract available


  126. HAWKINS PG, Lee JY, Mao Y, Li P, et al
    Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32502.
    PubMed     Text format     Abstract available


  127. HUIZING FJ, Hoeben BAW, Franssen G, Lok J, et al
    Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
    Radiother Oncol. 2017 Aug 5. pii: S0167-8140(17)32484.
    PubMed     Text format     Abstract available


  128. HOSNI A, McMullen C, Huang SH, Xu W, et al
    Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.
    Radiother Oncol. 2017;124:225-231.
    PubMed     Text format     Abstract available



  129. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison.
    Radiother Oncol. 2017;124:232-239.
    PubMed     Text format     Abstract available


  130. MAVROIDIS P, Price A, Fried D, Kostich M, et al
    Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Radiother Oncol. 2017;124:240-247.
    PubMed     Text format     Abstract available


  131. JURADO-BRUGGEMAN D, Hernandez V, Saez J, Navarro D, et al
    Multi-centre audit of VMAT planning and pre-treatment verification.
    Radiother Oncol. 2017;124:302-310.
    PubMed     Text format     Abstract available


  132. DELANEY AR, Dahele M, Tol JP, Kuijper IT, et al
    Using a knowledge-based planning solution to select patients for proton therapy.
    Radiother Oncol. 2017;124:263-270.
    PubMed     Text format     Abstract available


    July 2017
  133. MOHAMED ASR, Cardenas CE, Garden AS, Awan MJ, et al
    Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Radiother Oncol. 2017 Jul 31. pii: S0167-8140(17)32476.
    PubMed     Text format     Abstract available


  134. ZHAI TT, van Dijk LV, Huang BT, Lin ZX, et al
    Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters.
    Radiother Oncol. 2017 Jul 29. pii: S0167-8140(17)32472.
    PubMed     Text format     Abstract available


  135. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.
    Radiother Oncol. 2017 Jul 26. pii: S0167-8140(17)32470.
    PubMed     Text format     Abstract available


  136. NEVENS D, Duprez F, Daisne JF, De Neve W, et al
    Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.
    Radiother Oncol. 2017 Jul 24. pii: S0167-8140(17)32456.
    PubMed     Text format    


  137. RASSAMEGEVANON T, Lock S, Range U, Krause M, et al
    Tumor heterogeneity determined with a gammaH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models.
    Radiother Oncol. 2017 Jul 21. pii: S0167-8140(17)32447.
    PubMed     Text format     Abstract available


  138. XI M, Xu C, Liao Z, Hofstetter WL, et al
    The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Jul 4. pii: S0167-8140(17)30428.
    PubMed     Text format     Abstract available


  139. JIN P, Hulshof MCCM, van Wieringen N, Bel A, et al
    Interfractional variability of respiration-induced esophageal tumor motion quantified using fiducial markers and four-dimensional cone-beam computed tomography.
    Radiother Oncol. 2017;124:147-154.
    PubMed     Text format     Abstract available


    June 2017
  140. ZHANG D, Zhang W, Liu W, Mao Y, et al
    Human papillomavirus infection increases the chemoradiation response of esophageal squamous cell carcinoma based on P53 mutation.
    Radiother Oncol. 2017 Jun 21. pii: S0167-8140(17)30408.
    PubMed     Text format     Abstract available


  141. MCLAY M, Stedford A, Yurkowski E, Matlock S, et al
    Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients treated in a provincially coordinated radiotherapy program.
    Radiother Oncol. 2017 Jun 15. pii: S0167-8140(17)30401.
    PubMed     Text format     Abstract available


  142. BIRD D, Patel C, Scarsbrook AF, Cosgrove V, et al
    Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position.
    Radiother Oncol. 2017 Jun 6. pii: S0167-8140(17)30378.
    PubMed     Text format     Abstract available


  143. ZHANG W, Zhang X, Yang P, Blanchard P, et al
    Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
    Radiother Oncol. 2017;123:401-405.
    PubMed     Text format     Abstract available


  144. IKAWA H, Koto M, Takagi R, Ebner DK, et al
    Prognostic factors of adenoid cystic carcinoma of the head and neck in carbon-ion radiotherapy: The impact of histological subtypes.
    Radiother Oncol. 2017;123:387-393.
    PubMed     Text format     Abstract available


  145. CHEN AM, Chin R, Beron P, Yoshizaki T, et al
    Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer.
    Radiother Oncol. 2017;123:412-418.
    PubMed     Text format     Abstract available


    May 2017
  146. KOPPENHAGEN P, Dickreuter E, Cordes N
    Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
    Radiother Oncol. 2017 May 31. pii: S0167-8140(17)30375.
    PubMed     Text format     Abstract available


  147. CHEN J, Cai W, Zheng X, Chen Y, et al
    The pattern of cervical lymph node metastasis in thoracic esophageal squamous cell carcinoma may affect the target decision for definitive radiotherapy.
    Radiother Oncol. 2017 May 24. pii: S0167-8140(17)30152.
    PubMed     Text format     Abstract available


  148. LAI TY, Wang TH, Liu CJ, Chao TF, et al
    Risk factors for osteonecrosis of the jaw in oral cancer patients after surgery and eventual adjuvant treatment: The potential role of chemotherapy.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30362.
    PubMed     Text format     Abstract available


  149. FAN CY, Lin CS, Chao HL, Huang WY, et al
    Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30367.
    PubMed     Text format     Abstract available


  150. CHRISTIAENS M, Collette S, Overgaard J, Gregoire V, et al
    Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
    Radiother Oncol. 2017 May 4. pii: S0167-8140(17)30160.
    PubMed     Text format     Abstract available


    April 2017
  151. LIN SH, Merrell KW, Shen J, Verma V, et al
    Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.
    Radiother Oncol. 2017 Apr 25. pii: S0167-8140(17)30154.
    PubMed     Text format     Abstract available


  152. WELZ S, Monnich D, Pfannenberg C, Nikolaou K, et al
    Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
    Radiother Oncol. 2017 Apr 20. pii: S0167-8140(17)30144.
    PubMed     Text format     Abstract available


  153. RUSTHOVEN CG, Lanning RM, Jones BL, Amini A, et al
    Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
    Radiother Oncol. 2017 Apr 19. pii: S0167-8140(17)30130.
    PubMed     Text format     Abstract available


  154. ZHU H, Song H, Chen G, Yang X, et al
    eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Apr 18. pii: S0167-8140(17)30140.
    PubMed     Text format     Abstract available


  155. YAMASHITA H, Abe O, Nakagawa K
    Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
    Radiother Oncol. 2017 Apr 17. pii: S0167-8140(17)30141.
    PubMed     Text format    


  156. WU B, Kusters M, Kunze-Busch M, Dijkema T, et al
    Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).
    Radiother Oncol. 2017;123:57-62.
    PubMed     Text format     Abstract available


    March 2017
  157. NEVENS D, Duprez F, Daisne JF, Schatteman J, et al
    Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer.
    Radiother Oncol. 2017 Mar 22. pii: S0167-8140(17)30099.
    PubMed     Text format     Abstract available


  158. NAKAMURA N, Zenda S, Tahara M, Okano S, et al
    Proton beam therapy for olfactory neuroblastoma.
    Radiother Oncol. 2017;122:368-372.
    PubMed     Text format     Abstract available


    February 2017
  159. BERTHON B, Evans M, Marshall C, Palaniappan N, et al
    Head and neck target delineation using a novel PET automatic segmentation algorithm.
    Radiother Oncol. 2017;122:242-247.
    PubMed     Text format     Abstract available


  160. VAN LOON J, Even AJ, Aerts HJ, Ollers M, et al
    PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
    Radiother Oncol. 2017;122:267-273.
    PubMed     Text format     Abstract available


  161. BUSCH CJ, Kroger MS, Jensen J, Kriegs M, et al
    G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Radiother Oncol. 2017;122:260-266.
    PubMed     Text format     Abstract available


  162. KOVACS G, Martinez-Monge R, Budrukkar A, Guinot JL, et al
    GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update - Improvement by cross sectional imaging based treatment planning and stepping source technology.
    Radiother Oncol. 2017;122:248-254.
    PubMed     Text format     Abstract available


  163. HAMMING-VRIEZE O, van Kranen SR, Heemsbergen WD, Lange CA, et al
    Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy.
    Radiother Oncol. 2017;122:224-228.
    PubMed     Text format     Abstract available


  164. GRONLUND E, Johansson S, Montelius A, Ahnesjo A, et al
    Dose painting by numbers based on retrospectively determined recurrence probabilities.
    Radiother Oncol. 2017;122:236-241.
    PubMed     Text format     Abstract available


  165. SODERSTROM K, Nilsson P, Laurell G, Zackrisson B, et al
    Dysphagia - Results from multivariable predictive modelling on aspiration from a subset of the ARTSCAN trial.
    Radiother Oncol. 2017;122:192-199.
    PubMed     Text format     Abstract available


  166. NEVENS D, Duprez F, Daisne JF, Laenen A, et al
    Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for late fibrosis.
    Radiother Oncol. 2017;122:212-216.
    PubMed     Text format     Abstract available


  167. VAN DIJK LV, Brouwer CL, van der Schaaf A, Burgerhof JG, et al
    CT image biomarkers to improve patient-specific prediction of radiation-induced xerostomia and sticky saliva.
    Radiother Oncol. 2017;122:185-191.
    PubMed     Text format     Abstract available


  168. VAN DIJK LV, Langendijk JA, Sijtsema NM, Steenbakkers RJHM, et al
    Reply letter to "Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis".
    Radiother Oncol. 2017;122:322.
    PubMed     Text format    


  169. NARDONE V, Tini P, Nioche C, Biondi M, et al
    Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis.
    Radiother Oncol. 2017;122:321.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: